Since the launch of the national centralized procurement, the State Food and Drug Administration has attached great importance to the supervision of centralized procurement of drugs and medical devices, and the quality and safety of the drugs and medical devices selected by the national centralized procurement are in good condition.
Xu Jinghe, deputy director of the State Drug Administration: Since the start of the national centralized procurement, the State Food and Drug Administration has deployed and carried out special supervision of the selected drugs and medical devices in the centralized procurement every year, so as to realize the implementation of the national centralized procurement of selected drugs and medical devices The "three full coverage" of enterprise supervision and inspection, sampling inspection of products in production, and adverse drug reaction (medical device adverse events) monitoring have also been strongly affirmed by the National Medical Insurance Administration. The inspections involved nearly 600 drug manufacturers and nearly 170 medical device manufacturers; product sampling involved 333 drug varieties and 15 medical device varieties, effectively guaranteeing the quality and safety of selected drugs and medical devices in centralized procurement. At the same time, we have comprehensively strengthened the implementation of the main responsibility of enterprises and the implementation of local regulatory responsibilities. Judging from the work of supervision and inspection, supervision and random inspection, and monitoring of adverse reactions and adverse events, the quality and safety of drugs and medical devices selected by the national centralized procurement are in good condition.
微信扫一扫打赏
